Hunker downs boys. Fiscal cliff, debt ceiling, biosurgery profit, and Prochymal for AMI phase 2 data.
A combination of these factors will determine where Osiris goes from here. Good AMI data has the potential to trump everything because of the market size and likely early FDA approval if the data is convincing enough to hit the market while simultaneously running a phase 3. Can Osiris afford this in "go it alone" fashion?